The effectiveness of HSP90 inhibition by PU-H71 extends to a range of genetically diverse human cancers, highlighting the importance of conducting targeted drug trials with HSP90 inhibitors for treating MPNs and other malignancies (Gao et al., 2007; Hedvat et al., 2009). Here, HSP90AA1 is linked to cancer.